We are live on ! Find out more
SIOX

Sio Gene Therapies Inc. Common Stock
SIOX

Delisted

SIOX was delisted on the 22nd of March, 2023.

Back to rankings

62 hedge funds and large institutions have $39.7M invested in Sio Gene Therapies Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 8

80% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 15

27% more call options, than puts

Call options by funds: $1.71M | Put options by funds: $1.35M

24% more funds holding

Funds holding: 50 → 62 (+12)

24% less capital invested

Capital invested by funds: $52.3M → $39.7M (-$12.6M)

Holders
62
Holders Change
+12
Holders Change %
+24%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
16
Reduced
8
Closed
15
Calls
$1.71M
Puts
$1.35M
Net Calls
+$360K
Net Calls Change
+$780K

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$5.46M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.21M
3
SCM
Sio Capital Management
New York
+$2.58M
4
Morgan Stanley
Morgan Stanley
New York
+$1.02M
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$801K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$5.33M
2
CA
Corriente Advisors
Texas
-$4.04M
3
Renaissance Technologies
Renaissance Technologies
New York
-$2.04M
4
Two Sigma Investments
Two Sigma Investments
New York
-$1.42M
5
IC
Ikarian Capital
Texas
-$820K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
1
Consonance Capital Management
New York
$8.86M -$146K -50,000 -2%
RCMNY
2
Rubric Capital Management (New York)
New York
$6.49M +$5.46M +1,875,000 +407%
OM
3
Opaleye Management
Massachusetts
$5.56M -$114K -39,100 -2%
Hudson Bay Capital Management
4
Hudson Bay Capital Management
Connecticut
$4.45M +$801K +275,000 +21%
Vanguard Group
5
Vanguard Group
Pennsylvania
$3.06M +$3.21M +1,101,350 New
SCM
6
Sio Capital Management
New York
$2.46M +$2.58M +886,665 New
GCP
7
GSA Capital Partners
United Kingdom
$985K +$679K +233,340 +193%
Morgan Stanley
8
Morgan Stanley
New York
$983K +$1.02M +349,556 +8,073%
SCA
9
Sassicaia Capital Advisers
New York
$863K +$904K +310,500 New
Verition Fund Management
10
Verition Fund Management
Connecticut
$708K +$712K +244,684 +2,447%
AAA
11
Affinity Asset Advisors
New York
$695K +$728K +250,000 New
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$548K +$32.9K +11,301 +6%
JGC
13
J. Goldman & Co
New York
$351K +$367K +126,160 New
Connor, Clark & Lunn Investment Management (CC&L)
14
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$328K +$343K +117,832 New
SFI
15
Susquehanna Fundamental Investments
Pennsylvania
$276K +$235K +80,700 +434%
MS
16
Maven Securities
Jersey
$246K +$253K +86,788 New
Millennium Management
17
Millennium Management
New York
$218K -$53.1K -18,245 -19%
Citadel Advisors
18
Citadel Advisors
Florida
$190K +$17.4K +5,987 +10%
Capstone Investment Advisors
19
Capstone Investment Advisors
New York
$190K +$199K +68,481 New
Macquarie Group
20
Macquarie Group
Australia
$178K +$187K +64,170 New
Marshall Wace
21
Marshall Wace
United Kingdom
$171K +$179K +61,383 New
TSS
22
Two Sigma Securities
New York
$148K +$155K +53,148 New
Primecap Management
23
Primecap Management
California
$146K -$1.75K -600 -1%
Geode Capital Management
24
Geode Capital Management
Massachusetts
$133K +$72.2K +24,811 +108%
Creative Planning
25
Creative Planning
Kansas
$129K +$135K +46,275 New
1
2 3

SIOX Hedge Fund Activity: Q4 2020 in Review

62 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q4 2020, worth a combined $39.7M — down 24% from $52.3M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new SIOX positions and 15 closed out — a net gain of 12 holders — while 16 added to existing stakes and 8 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $5.46M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $5.33M sold.

  • 62 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q4 2020, up from 50 in Q3 2020.
  • Funds reported $39.7M of Sio Gene Therapies Inc. Common Stock stock for Q4 2020, down 24% quarter-over-quarter.
  • 27 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q4 2020 and 15 closed out, a net change of +12 holders.
  • The largest Sio Gene Therapies Inc. Common Stock buyer in Q4 2020 was Rubric Capital Management (New York), an estimated $5.46M added.
  • The largest Sio Gene Therapies Inc. Common Stock seller in Q4 2020 was Sphera Funds Management, an estimated $5.33M sold.

Based on aggregated 13F filings for Q4 2020.